Monday , June 18 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 22)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

August 23, 2016

Last week, I had a new patient referred to me with adult onset type 1 diabetes. The patient was 63 years old and — although she had been losing weight over the past year — it was a 16 pound loss over the previous 2 weeks that got the physician concerned. An A1c test came …

Read More »

August 20, 2016

Sometimes, when we want to impress our patients with the importance of their disease, we will list all the possible effects of the disease. These include blindness, kidney failure, and amputations. But what do we tell our patients that have pre-diabetes or impaired glucose tolerance? This week, we have an …

Read More »

August 18, 2016

For years the crux of diabetes care for type 2’s has been to reduce the amount of glucose going in and the amount of glucose being absorbed. We put patients on carbohydrate-restricted diets, have them take fiber before a meal, and use medicines such as acarbose. For the most part …

Read More »

August 16, 2016

If you are still stuck on the “metformin to start with and max out the dose” diabetes treatment algorithm, then you’d better take a look at this week’s homerun slides. Considering there are 11 distinct pathways to developing diabetes, it doesn’t make any sense that all our patients would only have …

Read More »

August 13, 2016

Last week the FDA announced that they were going to approve 6 different manufacturers for the production of rosuvastatin calcium, the generic version of Crestor. It appears that the FDA has decided that if they let more companies produce the generic, the price may not be as high to start …

Read More »

August 9, 2016

When a patient has a sudden and continued spike in glucose levels, we often look to check their insulin levels by ordering a C-Peptide test. We know that this test measures in vivo insulin based on the measurement of C-Peptide, which is co-secreted with insulin in equimolar amounts as a consequence …

Read More »

August 6, 2016

This past week, one of my favorite patients came back from a visit to Mississippi and was distraught. This patient was diagnosed with diabetes 6 years ago, and after significant weight loss he had to be placed on insulin. Being one of those people who believed he could “cure” his …

Read More »

August 2, 2016

We have all used the phrase “if you build it, they will come,” and when it comes to glucose monitoring systems and interconnectivity, it seems that every manufacturer has a belief that this is true. When Steve and Joy were at the recent ADA Scientific Sessions there were over 20 …

Read More »

July 30, 2016

There is an old saying in medicine: “above all do no harm.” This term often comes into play when our patients ask us about nutritional products for diabetes and other diseases, as well as when someone tells us about the greatest new exercise program to “cure” diabetes. This week we …

Read More »

July 26, 2016

There are various hormones, neurotransmitters, nucleotides, and fatty acids in the pancreas that affect insulin production and secretion. Sorting all these factors out, and how we might possibly affect glucose control by mimicking  some of these compounds, has opened up new avenues of treatment. GLP-1 agonists are just one example. This week in our …

Read More »